X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · IEX Real-Time Price · USD
1.71
+0.22 (14.77%)
Sep 30, 2022 4:00 PM EDT - Market closed
14.77%
Market Cap 117.38M
Revenue (ttm) n/a
Net Income (ttm) -101.52M
Shares Out 68.65M
EPS (ttm) -3.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,906,224
Open 1.50
Previous Close 1.49
Day's Range 1.49 - 1.86
52-Week Range 0.86 - 6.18
Beta 0.73
Analysts Buy
Price Target 6.29 (+267.8%)
Earnings Date Nov 2, 2022

About XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macr... [Read more...]

Industry Biotechnology
Founded 2014
Employees 83
Stock Exchange NASDAQ
Ticker Symbol XFOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for XFOR stock is "Buy." The 12-month stock price forecast is 6.29, which is an increase of 267.84% from the latest price.

Price Target
$6.29
(267.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropen...

100% of study participants (n=25) achieved robust responses to oral mavorixafor

5 days ago - GlobeNewsWire

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A

1 month ago - GlobeNewsWire

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago - Zacks Investment Research

X4 Pharmaceuticals to Present at Canaccord Genuity's 42nd Annual Growth Conference

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with ...

1 month ago - GlobeNewsWire

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global, pivotal Phase 3 trial in WHIM syndrome, expected in...

1 month ago - GlobeNewsWire

X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August...

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with...

2 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expecte...

Company now focused on advancing lead clinical candidate mavorixafor in  chronic neutropenic disorders, including WHIM syndrome

2 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with ...

3 months ago - GlobeNewsWire

X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-O...

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with ra...

3 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mec...

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with rar...

4 months ago - GlobeNewsWire

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of -16.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

X4 Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22

4 months ago - GlobeNewsWire

X4 Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 12,...

BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with di...

4 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with d...

5 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present at April Investor Conferences

BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with d...

5 months ago - GlobeNewsWire

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome  expected in 4Q22

6 months ago - GlobeNewsWire

X4 Pharmaceuticals to Announce Fourth Quarter 2021 Financial Results and Host a Conference Call and Webcast on March ...

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients wit...

6 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present at March Investor Conferences

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with...

6 months ago - GlobeNewsWire

X4 Pharmaceuticals to Present at B. Riley Securities Oncology Investor Conference

BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with di...

8 months ago - GlobeNewsWire

Why Did X4 Pharmaceuticals Shares Crater To 52-Week Low?

X4 Pharmaceuticals Inc (NASDAQ: XFOR) shares are trading lower despite releasing what it described as positive phase 2 data for mavorixafor for WHIM syndrome, a rare congenital immune deficiency. In a p...

9 months ago - Benzinga

X4 Pharmaceuticals Presents New Clinical and Scientific Data at 2021 ASH Annual Meeting Supporting Broader Potential ...

- Presented data highlight mavorixafor's ability to raise the spectrum of white blood cell counts across a broad range of diseases with or without CXCR4 mutations  including Chronic Neutropenia -

9 months ago - GlobeNewsWire

X4 Pharmaceuticals Presents New Clinical Data at ASH 2021 Further Supporting Potential of Mavorixafor + Ibrutinib to ...

- CXCR4 antagonism proof of concept established, with 100% overall response rate  to combination treatment in frontline and refractory patients -

9 months ago - GlobeNewsWire

X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market ...

Company to present new clinical data supporting the expanded potential use of mavorixafor to treat a broad array of immunodeficiencies as well as new insights into WHIM syndrome

10 months ago - GlobeNewsWire

X4 Pharmaceuticals to Participate in Stifel's Virtual Healthcare Conference

BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with di...

10 months ago - GlobeNewsWire

X4 Pharmaceuticals to Have Strong Presence at ASH 2021 with Seven Accepted Abstracts Highlighting New Clinical and Sc...

Data continue to support mavorixafor's potential to benefit patients with WHIM syndrome, chronic neutropenia, and Waldenström's macroglobulinemia

10 months ago - GlobeNewsWire